Treatment outcomes of patients with classic and AIDS-related Kaposi Sarcoma: a single-center real-world experience

Bryan Valcarcel-Valdivia, Daniel Enriquez-Vera, Luis Enrique Piedra, Alexis Holguín, Gabriel De la Cruz Ku

Producción científica: Contribución a una revistaArtículorevisión exhaustiva

Resumen

The recommended first-line chemotherapy agents for managing Kaposi sarcoma (KS) in high-income countries are expensive and often unavailable in developing nations such as Peru. Limited data exist on whether management practices in these countries affect patient outcomes. We assessed the real-world treatment approaches and outcomes of patients with KS in Peru. We retrospectively reviewed the medical records of patients with acquired immunodeficiency syndrome-related KS (AIDS-related KS; n = 95) and classic KS (CKS; n = 81) diagnosed at a tertiary center between 2000 and 2014 in Lima, Peru. We used the Kaplan–Meier method to estimate overall survival (OS) rates. The median follow-up was 64 months for AIDS-related KS and 88 months for CKS. The median age of patients with AIDS-related KS was 35 years (range 20–63 years) and 70 years (range 33–91 years) for those with CKS. Most individuals had an Eastern Cooperative Oncology Group performance status of ≥ 2 (AIDS-related KS 75%; CKS 85%). Seventy-six percent and 40% of individuals with AIDS-related KS and CKS, respectively, received systemic chemotherapy. The most common first-line drug was paclitaxel, with relatively optimal overall response rates (ORRs) for AIDS-related KS (n = 64/72, 89%; ORR 61%) and CKS (n = 24/32, 75%; ORR 50%). The 5-year OS rates were 71% in the AIDS-related KS cohort and 81% in the CKS cohort. The findings from this real-world study may inform clinical practices and highlight the need for increased access to effective treatments and clinical trials for patients with KS in Peru and other developing countries.

Idioma originalInglés
Páginas (desde-hasta)5463-5471
Número de páginas9
PublicaciónClinical and Experimental Medicine
Volumen23
N.º8
DOI
EstadoPublicada - dic. 2023

Huella

Profundice en los temas de investigación de 'Treatment outcomes of patients with classic and AIDS-related Kaposi Sarcoma: a single-center real-world experience'. En conjunto forman una huella única.

Citar esto